Table 3: Antibiotics for Vancomycin Resistant Staph aureus [17,34,49-51].
Table 3a: Oxazolidinones.
| Drug Name | Year FDA Approved | Notes |
| Linezolid | 2000 |
• Protein synthesis inhibition through P site binding of ribosomal 50S subunit interfering with peptidyl transferase and peptide bond formation. • Resistance profile is superior to other protein synthesis inhibitors. • Rare oxazolidinone resistance due to alterations of 23S rRNA has been reported but remains uncommon. • IDSA recommends usage in persistent MRSA bacteremia or vancomycin treatment failure. • Treatment failures have been noted in adults. |
| Tedizolid phosphate | 2014 |
• A second-generation oxazolidinone with superior activity against resistant Gram-positive organisms compared with linezolid. • FDA approved for ABSSI |